

EUROPEAN  
CURRICULUM VITAE  
FORMAT



PERSONAL INFORMATION



PEREGO PAOLA; Italian, 12/07/1965; [paola.perego@istitutotumori.mi.it](mailto:paola.perego@istitutotumori.mi.it); tel. 39-0223902237

WORK EXPERIENCE

• Dates

1989-present, Researcher in the field of **preclinical pharmacology** with different positions (fellow, researcher, senior researcher, staff scientist as team leader from 2000) at Fondazione IRCCS, **Istituto Nazionale dei Tumori** – via Venezian 1 – 20133 Milan, Italy

• Dates

1994-1996; Visiting Scientist at **University of California, San Diego, UCSD Cancer Center**, La Jolla, CA 92093-0819 USA – Laboratory of Molecular Pharmacology directed by Prof. S.B. Howell

EDUCATION AND TRAINING

• Dates

**2006-2009**; Università degli Studi di Verona, PhD course in Translational Biomedicine

• Title of qualification awarded

PhD in Translational Biomedicine

• Dates

**1990-91/1993-94**; Università degli Studi di Milano, Applied Genetics Specialization School

• Title of qualification awarded

Diploma of specialization in Applied Genetics

• Dates

**1989**; Università degli Studi di Milano Degree in Biology (110/110 cum laude)

• Dates

**1984**; Liceo Classico B. Zucchi, Monza Maturità classica (60/60)

ADDITIONAL INFORMATION

Member of: AACR from 1995, **EORTC-PAMM** (Pharmacology and Molecular Mechanisms Group) from 2005; **PAMM committee** from 2015; **EORTC-TRAC** (Translational Research Advisory Committee) from 03/2016; institutional scientific board from 2012; Fondazione Berlucci's scientific Board from 2016. Member of the Editorial Board of International Journal of Oncology (from 2009), of Current Drug Resistance (from end of 2013), of Current Medicinal Chemistry (from 2016). From November 2014, Section Editor (Preclinical Pharmacology) of Tumori Journal.

**Publicazioni:** **143 papers** published in peer-reviewed journals and several book chapters; H index = 38 (Scopus, February 2017)

**Patents:** "New anticancer compounds" Università degli Studi di Milano; Fondazione IRCCS Istituto Nazionale dei Tumori; Università degli Studi dell'Insubria. Italy PCT/IBI201300116 30/01/2013; "New SMAC mimetic compounds as apoptosis inducers" Università degli Studi di Milano, Fondazione IRCCS Istituto Nazionale dei Tumori CISI srl; PCT/IBI20 12/000297 - 20/02/2012.

**Selected recent publications**

1. **Perego P.**, Robert J. Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy. *Cancer Chemother Pharmacol.*, 2016; 77(1):5-18
2. Bertolini G, D'Amico L, Moro M, Landoni E, **Perego P**, Miceli R, Gatti L, Andriani F, Wong D, Caserini R, Tortoreto M, Milione M, Ferracini R, Mariani L, Pastorino U, Roato I, Sozzi G, Roz L. Microenvironment modulated metastatic CD133+/CXCR4+/EpCAM- lung cancer initiating cells sustain tumor dissemination and correlate with poor prognosis. *Cancer Res.* 2015; 75 (17):3636-49
3. Gatti L., Cassinelli G., Zaffaroni N., Lanzi C., **Perego P.** New mechanisms for old drugs: insights into DNA unrelated effects of platinum compounds and drug resistance determinants. *Drug Resistance Updates*, 2015; 20:1-11.
4. .Zuco V., Cassinelli G., Cossa G., Gatti L., Favini E., Tortoreto M., Cominetti D., Scanziani E., Castiglioni V., Cincinelli R., Giannini G., Zunino F., Zaffaroni N., Lanzi C., **Perego P.** Targeting the invasive phenotype of cisplatin-resistant non-small lung cancer cells by a novel histone deacetylase inhibitor. *Biochemical Pharmacology*, 2015; 94 (2):79-90
5. Gatti L, Sevko A, De Cesare M, Arrighetti A, Manenti G, Ciusani E, Verderio P, Ciniselli CM, Cominetti D, Carenini N, Corna E, Zaffaroni N, Rodolfo M, Rivoltini L, Umansky V, **Perego P.** Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals. *Oncotarget* 2014; 5:4516-28
6. Gomez-Lira M, Ferronato S, Malerba G, Santinami M, Maurichi A, Sangalli A, Turco A, **Perego P**, Rodolfo M. Association of promoter polymorphism -765G>C in the PTGS2 gene with malignant melanoma in Italian patients and its correlation to gene expression in dermal fibroblasts. *Exp Dermatol.* 2014; 23 (10):766-8
7. Cossa G, Lanzi C, Cassinelli G, Carenini N, Arrighetti N, Gatti L, Corna E, Zunino F, Zaffaroni N, **Perego P.** Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells. *Cancer Lett.* 2014; 347:212-24
8. Gatti L, Cossa G, Tinelli S, Carenini N, Arrighetti N, Pennati M, Cominetti D, De Cesare M, Zunino F, Zaffaroni N, **Perego P.** Improved apoptotic cell death in drug-resistant non small cell lung cancer cells by TRAIL-based treatment. *J Pharmacol Exp Ther.*, 2014; 348:360-71
9. D'Arcy P, Brnjic S., Olofsson MH, Fryknäs M, Lindsten K, De Cesare M, **Perego P**, Sadeghi B, Hassan M, Larsson R and Linder S. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. *Nat Med.* 2011; 17:1636-40.
10. Vergani, E., Vallacchi, V., Frigerio, S., Deho, P., Mondellini, P., **Perego, P.**, Cassinelli, G., Lanzi, C., Testi, M.A., Rivoltini, L., Bongarzone, I., Rodolfo, M. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. *Neoplasia*, 2011; 13 (12): 1132-1142.